Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859120 | 0.79 | PARP1 (0.56) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL616606 | 0.79 | MAPT (0.41) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL4157390 | 0.76 | PARP1 (0.41) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL20910011 | 0.76 | PARP1 (0.41) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL20385466 | 0.76 | KMT2A (0.49) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL17591328 | 0.76 | PNP (0.46) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL29804933 | 0.76 | MEN1 (0.44) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL1144726 | 0.76 | MEN1 (0.44) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL12277149 | 0.76 | MAPT (0.36) | PARP1KMT2AMEN1MAPTPNP | |
| SCHEMBL30477591 | 0.76 | CTSS (0.38) | KMT2AMEN1MAPTPNPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023143247-A1 | LINKER FOR CHARACTERIZING SEQUENCING OF TARGET POLYNUCLEOTIDE, CONSTRUCT, METHOD, AND USE | 成都齐碳科技有限公司 | 2023-08-03 | — | — | WO | claimed |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| CN-114457145-A | Linkers, constructs, methods, and uses for characterizing sequencing of target polynucleotides | 成都齐碳科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| US-20210292757-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-09-23 | — | — | US | claimed |
| EP-3865576-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| US-10870849-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | claimed |
| US-10837013-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | claimed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | claimed |
| US-20150038554-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20150038555-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| US-20130041010-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | claimed |
| US-20110288147-A1 | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop | DICERNA PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | claimed |
| EP-2341943-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | Dicerna Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| US-20100331389-A1 | Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides | DICERNA PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2010033225-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | claimed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | PARP1 711/4885KMT2A 2367/4885MEN1 1927/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | PARP1 1343/4885KMT2A 3305/4885MEN1 4354/4885 |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | PARP1 4093/4885KMT2A 3074/4885MEN1 1797/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | PARP1 377/4885KMT2A 792/4885MEN1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.